시장보고서
상품코드
1263188

세계 의약품 위탁생산 시장 : 서비스별(의약품(API, FDF(정제, 캡슐, 주사제), 생물학적제제(API, FDF), 의약품 개발), 최종사용자별(대형 제약 기업, 중소 제약 기업, 제네릭 의약품 기업), 지역별 예측(-2028년)

Pharmaceutical Contract Manufacturing Market by Service (Pharmaceutical (API, FDF - Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) - Global Forecast to 2028

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 279 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

글로벌 의약품 위탁 개발 및 제조 시장 규모는 2023년 1,765억 달러에서 2028년 2,583억 달러로 예측 기간 동안 7.9%의 CAGR을 기록할 것으로 예상됩니다.

저렴한 비용으로 인한 제네릭 의약품의 수요 증가와 블록버스터 의약품의 특허 만료가 임박한 등의 요인으로 인해 기업들은 핵심 기능에 집중하게 되었고, 이는 CDMO 서비스에 대한 수요를 뒷받침하고 시장 성장을 가속화하고 있습니다.

"생물학적 제제 제조 서비스 부문은 예측 기간(2023-2028년) 동안 가장 높은 CAGR로 성장할 것입니다."

바이오의약품 제조 서비스 부문은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이러한 성장은 생물학적 제제에 대한 수요 증가, 표적치료제, 세포 및 유전자 치료 파이프라인 연구 증가 등에 기인합니다. 이러한 요인들은 부문별 성장에 긍정적인 영향을 미칠 것으로 보입니다.

"대형 제약사 부문은 예측 기간(2023-2028년) 동안 가장 높은 CAGR로 성장할 것"

제약 위탁 개발 및 제조 시장에서는 2022년 주요 제약사 부문이 압도적인 점유율을 차지할 것으로 예상됩니다. 이 부문의 큰 점유율은 제약 회사가 새로운 분자 발견 및 개발을 위한 연구 개발 증가와 같은 핵심 활동에 중점을 두면서 제조 서비스 아웃소싱을 늘리고 있기 때문입니다. 이는 시장 성장을 예측하게 하는 주요 요인 중 하나입니다.

"아시아태평양은 더 빠른 속도로 성장할 것입니다."

2022년, 북미는 의약품 위탁 개발 및 제조 시장에서 압도적인 점유율을 차지할 것으로 예상됩니다. 이 지역의 우위는 이 지역의 주요 기업들과 지속적인 의약품 위탁 개발 및 제조 연구 활동 등 다양한 요인에 기인합니다. 아태지역은 개인 맞춤형 치료에 대한 관심 증가, 제네릭 의약품에 대한 정부 정책 강화, 의약품 위탁 개발 및 제조 시장에 신규 진입하는 기업 등 다양한 요인으로 인해 더 빠른 속도로 성장할 것으로 예상됩니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
  • 밸류체인 분석
  • 에코시스템 분석
  • 기술 분석
  • Porter의 Five Forces 분석
  • 규제 분석
  • 주요 컨퍼런스 및 이벤트(2022년-2023년)
  • 주요 이해관계자와 구입 기준
  • 고객의 비즈니스에 영향을 미치는 동향/혼란
  • ANDA 승인

제6장 의약품 위탁생산 시장 : 서비스별

  • 서론
  • 의약품 제조 서비스
    • 의약품 API(원료의약품) 제조 서비스
    • 의약품 FDF(완성제형) 제조 서비스
  • 의약품 개발 서비스
  • 생물제제 제조 서비스
    • 생물제제 API(원료의약품) 제조 서비스
    • 생물제제 FDF(완성제형) 제조 서비스

제7장 의약품 위탁생산 시장 : 최종사용자별

  • 서론
  • 대형 제약 기업
  • 중소 제약 기업
  • 제네릭 의약품 기업
  • 기타 최종사용자

제8장 의약품 위탁생산 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스위스
    • 폴란드
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카

제9장 경쟁 구도

  • 개요
  • 주요 기업 전략
  • 매출 점유율 분석
  • 시장 점유율 분석
  • 주요 기업 기업 평가 쿼드런트(2022년)
  • 상위 25사 경쟁 벤치마킹
  • 스타트업/중소기업용 기업 평가 쿼드런트(2022년)
  • 스타트업/중소기업의 경쟁 벤치마킹
  • 경쟁 시나리오와 동향

제10장 기업 개요

  • 주요 기업
    • THERMO FISHER SCIENTIFIC, INC.
    • CATALENT, INC.
    • LONZA GROUP
    • ABBVIE, INC.
    • WUXI APPTEC
    • EVONIK INDUSTRIES AG
    • SAMSUNG BIOLOGICS
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • SIEGFRIED HOLDING AG
    • FUJIFILM HOLDINGS CORPORATION
    • EUROFINS SCIENTIFIC
    • PIRAMAL PHARMA SOLUTIONS
    • RECIPHARM AB
    • ALMAC GROUP
    • VETTER PHARMA
  • 기타 기업
    • DELPHARM HOLDINGS
    • YUHAN CORPORATION
    • CURIA GLOBAL, INC.
    • CHARLES RIVER LABORATORIES
    • LANNETT COMPANY, INC.
    • CAMBREX CORPORATION
    • FAMAR HEALTHCARE SERVICES
    • SYNGENE INTERNATIONAL LIMITED(BIOCON LIMITED)
    • SAI LIFE SCIENCES LIMITED
    • PCI PHARMA SERVICES

제11장 부록

LSH 23.05.10

The global pharmaceutical contract development and manufacturing market size is projected to reach USD 258.3 billion by 2028 from USD 176.5 billion in 2023, at a CAGR of 7.9% during the forecast period. Factors such as increasing demand for generics due to their low cost and the looming patent expiry of blockbuster medications have pushed companies to focus on core functions, supporting the demand for CDMO services, and driving the market growth at a faster pace.

"The biologic manufacturing service segment is likely to grow at the highest CAGR during the forecast period of 2023-2028."

On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing service, drug development service, and biologic manufacturing service. The biologic manufacturing service segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising demand for biologics, targeted drug therapies, and increase in the number cell & gene therapy pipeline studies. These factors are likely to have a positive impact on segmental growth.

"The big pharmaceutical companies segment is likely to grow at the highest CAGR during the forecast period of 2023-2028."

Based on end user, the pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small and midsized pharmaceutical companies, generic pharmaceutical companies, and other end users (Academic Institutes, Small CDMOs, and CROs). The big pharmaceutical companies segment held a dominant share of the pharmaceutical contract development and manufacturing market, in 2022. The large share of this segment is attributed to the growing focus of pharma giants on core activities like increasing R&D for the discovery & development of new molecules, pushing them to outsource the manufacturing services. This is one of the major factors anticipated to project market growth.

"Asia Pacific region is likely to grow at a faster pace."

The pharmaceutical contract development and manufacturing market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract development and manufacturing. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising government initiatives for generic medicines in the region, and the emergence of new market players in the pharmaceutical contract development and manufacturing market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60%, and Demand Side - 40%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 25%, Executives- 15%, Other -15.0%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Catalent, Inc. (US)
  • Lonza Group (Switzerland)
  • AbbVie, Inc. (US)
  • WuXi AppTec (China)
  • Evonik Industries AG (Germany)
  • Samsung Biologics. (South Korea)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Siegfried Holding AG (Switzerland)
  • Piramal Pharma Solutions (India)
  • Recipharm AB. (Sweden)
  • Eurofins Scientific (Luxembourg)
  • FUJIFILM Holdings Corporation (Japan)
  • Almac Group (UK)
  • Vetter Pharma (Germany)
  • Delpharm Holdings (France)
  • Yuhan Corporation (South Korea)
  • Curia Global, Inc. (US)
  • Charles River Laboratories. (US)
  • Lannett Company, Inc. (US)
  • Cambrex Corporation. (US)
  • FAMAR Healthcare Services (France)
  • Biocon Limited (India)
  • Sai Life Sciences Limited (India)
  • PCI Pharma Services (US).

Research Coverage:

This report provides a detailed picture of the pharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as service, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.
  • Service Development/Innovation: Detailed insights on newly launched services, and technological assessment of the pharmaceutical contract development and manufacturing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the pharmaceutical contract development and manufacturing market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the pharmaceutical contract development and manufacturing market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China) and among others in the pharmaceutical contract development and manufacturing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 STAKEHOLDERS
  • 1.7 LIMITATIONS
  • 1.8 SUMMARY OF CHANGES
  • 1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY SERVICE AND END USER)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: CAGR PROJECTIONS, 2023-2028
    • FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 IMPACT ANALYSIS OF RECESSION ON PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2027 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW
    • FIGURE 15 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE & COUNTRY (2022)
    • FIGURE 16 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET TILL 2028
  • 4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY END USER, 2022
    • FIGURE 18 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increased investment in precision medicines
      • 5.2.1.2 Patent expiry & increasing demand for generic drugs
    • TABLE 5 IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS, BY YEAR
      • 5.2.1.3 High cost of in-house drug development
    • FIGURE 21 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
      • 5.2.1.4 Investments in advanced manufacturing technologies by CDMOs
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Varying regulatory requirements across regions
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for cell & gene therapy
    • TABLE 6 EXPANSIONS BY TOP COMPANIES IN 2022
      • 5.2.3.2 Growing inclination toward one-stop-shop model
      • 5.2.3.3 Market expansion in emerging countries
      • 5.2.3.4 Growth of nuclear medicine
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Introduction of serialization
      • 5.2.4.2 Intellectual property risk
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS: API PRODUCTION AND FORMULATION ADD MAXIMUM VALUE
  • 5.4 ECOSYSTEM ANALYSIS
    • FIGURE 23 ECOSYSTEM ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: ROLE IN ECOSYSTEM
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 THREAT OF SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF SUPPLIERS
    • 5.6.4 BARGAINING POWER OF BUYERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 REGULATORY SCENARIO IN DIFFERENT COUNTRIES
  • 5.8 KEY CONFERENCES & EVENTS, 2022-2023
    • TABLE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022-2023
  • 5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES
    • 5.9.2 BUYING CRITERIA
    • FIGURE 25 KEY BUYING CRITERIA FOR END USERS
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
    • FIGURE 26 REVENUE SHIFT & NEW POCKETS FOR PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 5.11 ANDA APPROVALS
    • FIGURE 27 ANDA APPROVALS, 2018-2022
    • FIGURE 28 REGIONAL BREAKDOWN OF ANDA APPROVALS IN 2022
    • FIGURE 29 ANDA APPROVALS IN 2022, BY DOSAGE FORM

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    • TABLE 16 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 17 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 18 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 19 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 20 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 21 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
      • 6.2.1.1 Need to focus on core areas to drive pharma companies to outsource API manufacturing
    • TABLE 22 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 23 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 24 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 25 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 26 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
    • TABLE 27 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 28 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 29 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 30 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 31 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 32 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.1 Parenteral/Injectable manufacturing services
        • 6.2.2.1.1 Increasing investments in drug development to support market growth
    • TABLE 33 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 34 NORTH AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 35 EUROPE: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 36 ASIA PACIFIC: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 37 LATIN AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.2 Tablet manufacturing services
        • 6.2.2.2.1 Growing production capacity for tablet manufacturing in emerging markets to support growth
    • TABLE 38 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 39 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 40 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 41 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 42 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.3 Capsule manufacturing services
        • 6.2.2.3.1 Popularity of capsules to ensure demand for contract manufacturing
    • TABLE 43 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 44 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 45 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 46 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 47 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.4 Oral liquid manufacturing services
        • 6.2.2.4.1 Complexities in handling liquids to promote outsourcing
    • TABLE 48 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 49 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 50 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 51 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 52 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.5 Semi-solid manufacturing services
        • 6.2.2.5.1 Need for specialized facilities to boost outsourcing of semi-solid manufacturing
    • TABLE 53 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 54 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 55 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 56 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 57 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.6 Other FDF manufacturing services
    • TABLE 58 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 59 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 60 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 61 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 62 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.3 DRUG DEVELOPMENT SERVICES
    • 6.3.1 HIGH COST OF DEVELOPMENT TO BOOST OUTSOURCING
    • TABLE 63 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 64 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 65 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 66 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 67 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.4 BIOLOGIC MANUFACTURING SERVICES
    • TABLE 68 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 69 BIOLOGIC MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 70 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 71 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 72 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 73 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.4.1 BIOLOGIC API MANUFACTURING SERVICES
      • 6.4.1.1 Rising interest in biologics to ensure growth of nascent contract manufacturing sector
    • TABLE 74 BIOLOGIC API MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 75 NORTH AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 76 EUROPE: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 77 ASIA PACIFIC: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 78 LATIN AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.4.2 BIOLOGIC FDF MANUFACTURING SERVICES
      • 6.4.2.1 Growing R&D costs and process complexity to favor contract manufacturing
    • TABLE 79 BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 80 NORTH AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 81 EUROPE: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 82 ASIA PACIFIC: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 83 LATIN AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 84 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 7.2 BIG PHARMACEUTICAL COMPANIES
    • 7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO MARKET GROWTH
    • TABLE 85 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 86 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 87 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 89 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    • 7.3.1 GROWING DEVELOPMENT OF BIOLOGICS AND HIGH PRICING PRESSURE TO BOOST MARKET
    • TABLE 90 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 91 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 92 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 93 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 94 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    • 7.4.1 RISING DEMAND FOR GENERICS TO PROPEL MARKET
    • TABLE 95 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 96 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 97 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 98 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 99 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.5 OTHER END USERS
    • TABLE 100 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 101 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 102 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 103 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 104 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 105 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021-2028 (USD BILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 106 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 108 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 109 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 110 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 111 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.2.1 US
      • 8.2.1.1 US to dominate North American market
    • TABLE 112 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 113 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 114 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 115 US: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 116 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Rising government funding and support to propel market
    • TABLE 117 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 118 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 119 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 120 CANADA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 121 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.2.3 NORTH AMERICA: RECESSION IMPACT
  • 8.3 EUROPE
    • TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 123 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 124 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 125 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 126 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 127 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Germany to hold largest share throughout forecast period
    • TABLE 128 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 129 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 130 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 131 GERMANY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 132 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.2 UK
      • 8.3.2.1 Rising investments in drug development to favor market growth
    • TABLE 133 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 134 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 135 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 136 UK: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 137 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Growing generics segment, favorable government policies, and growing clinical trials to drive market
    • TABLE 138 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 139 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 140 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 141 FRANCE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 142 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Rising commercial drug development pipeline in Europe to favor market growth
    • TABLE 143 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 144 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 145 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 146 ITALY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 147 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.5 SWITZERLAND
      • 8.3.5.1 Growing pharmaceutical industry to support growth
    • TABLE 148 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 149 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 150 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 151 SWITZERLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 152 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.6 POLAND
      • 8.3.6.1 Increasing support for life science R&D to propel market
    • TABLE 153 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 154 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 155 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 156 POLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 157 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.7 SPAIN
      • 8.3.7.1 Rising R&D expenditure to boost market
    • TABLE 158 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 159 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 160 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 161 SPAIN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 162 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.8 REST OF EUROPE
    • TABLE 163 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 164 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 165 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 166 REST OF EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 167 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.9 EUROPE: RECESSION IMPACT
  • 8.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 168 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 170 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 171 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 172 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 173 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 China to hold largest share of Asia Pacific market
    • TABLE 174 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 175 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 176 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 177 CHINA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 178 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.2 INDIA
      • 8.4.2.1 Increasing pharma R&D activities and government funding for biotechnology to support market growth
    • TABLE 179 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 180 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 181 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 182 INDIA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 183 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.3 JAPAN
      • 8.4.3.1 Growing generics demand and government initiatives to drive demand for contract manufacturing
    • TABLE 184 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 185 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 186 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 187 JAPAN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 188 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.4 SOUTH KOREA
      • 8.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
    • TABLE 189 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 190 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 191 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 192 SOUTH KOREA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 193 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.5 REST OF ASIA PACIFIC
    • TABLE 194 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 195 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 196 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 197 REST OF ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 198 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 8.5 LATIN AMERICA
    • TABLE 199 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 200 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 201 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 202 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 203 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.5.1 BRAZIL
      • 8.5.1.1 Growing pharmaceutical industry to drive market
    • TABLE 205 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 206 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 207 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 208 BRAZIL: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 209 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.5.2 REST OF LATIN AMERICA
    • TABLE 210 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 211 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 212 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 213 REST OF LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 214 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.5.3 LATIN AMERICA: RECESSION IMPACT
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 UAE AND SAUDI ARABIA TO SHOW SIGNIFICANT GROWTH
    • TABLE 215 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 216 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 217 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 218 MIDDLE EAST & AFRICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 219 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 KEY PLAYER STRATEGIES
    • TABLE 220 KEY STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, 2020-2023
  • 9.3 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 9.4 MARKET SHARE ANALYSIS
    • FIGURE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
    • TABLE 221 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
  • 9.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
    • FIGURE 34 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT, 2022
  • 9.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 9.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 222 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • 9.6.2 END-USER FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 223 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • 9.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 224 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2022)
    • 9.7.1 PROGRESSIVE COMPANIES
    • 9.7.2 STARTING BLOCKS
    • 9.7.3 RESPONSIVE COMPANIES
    • 9.7.4 DYNAMIC COMPANIES
    • FIGURE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
  • 9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 225 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 226 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • 9.9 COMPETITIVE SCENARIO AND TRENDS
    • 9.9.1 SERVICE LAUNCHES
    • TABLE 227 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2020-MARCH 2023
    • 9.9.2 DEALS
    • TABLE 228 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, JANUARY 2020-MARCH 2023
    • 9.9.3 OTHER DEVELOPMENTS
    • TABLE 229 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020-MARCH 2023

10 COMPANY PROFILES

  • 10.1 KEY MARKET PLAYERS
  • (Business Overview, Services Offered, Recent Developments, and MnM View)**
    • 10.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 230 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.2 CATALENT, INC.
    • TABLE 231 CATALENT, INC.: BUSINESS OVERVIEW
    • FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.3 LONZA GROUP
    • TABLE 232 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 38 LONZA GROUP: COMPANY SNAPSHOT (2022)
    • 10.1.4 ABBVIE, INC.
    • TABLE 233 ABBVIE, INC.: BUSINESS OVERVIEW
    • FIGURE 39 ABBVIE, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.5 WUXI APPTEC
    • TABLE 234 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022)
    • 10.1.6 EVONIK INDUSTRIES AG
    • TABLE 235 EVONIK INDUSTRIES AG: BUSINESS OVERVIEW
    • FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2022)
    • 10.1.7 SAMSUNG BIOLOGICS
    • TABLE 236 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
    • 10.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TABLE 237 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
    • FIGURE 43 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
    • 10.1.9 SIEGFRIED HOLDING AG
    • TABLE 238 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
    • FIGURE 44 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2022)
    • 10.1.10 FUJIFILM HOLDINGS CORPORATION
    • TABLE 239 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
    • 10.1.11 EUROFINS SCIENTIFIC
    • TABLE 240 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 10.1.12 PIRAMAL PHARMA SOLUTIONS
    • TABLE 241 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
    • FIGURE 47 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
    • 10.1.13 RECIPHARM AB
    • TABLE 242 RECIPHARM AB: BUSINESS OVERVIEW
    • 10.1.14 ALMAC GROUP
    • TABLE 243 ALMAC GROUP: BUSINESS OVERVIEW
    • 10.1.15 VETTER PHARMA
    • TABLE 244 VETTER PHARMA: BUSINESS OVERVIEW
  • * Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
  • 10.2 OTHER PLAYERS
    • 10.2.1 DELPHARM HOLDINGS
    • 10.2.2 YUHAN CORPORATION
    • 10.2.3 CURIA GLOBAL, INC.
    • 10.2.4 CHARLES RIVER LABORATORIES
    • 10.2.5 LANNETT COMPANY, INC.
    • 10.2.6 CAMBREX CORPORATION
    • 10.2.7 FAMAR HEALTHCARE SERVICES
    • 10.2.8 SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED)
    • 10.2.9 SAI LIFE SCIENCES LIMITED
    • 10.2.10 PCI PHARMA SERVICES

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제